|
Name |
Sphaeropsidin E
|
Molecular Formula | C20H32O3 | |
IUPAC Name* |
(1S,2R,4S,4bS,8aS,10R)-2-ethenyl-2,4b,8,8-tetramethyl-3,4,5,6,7,8a,9,10-octahydro-1H-phenanthrene-1,4,10-triol
|
|
SMILES |
C[C@]12CCCC([C@@H]1C[C@H](C3=C2[C@H](C[C@]([C@@H]3O)(C)C=C)O)O)(C)C
|
|
InChI |
InChI=1S/C20H32O3/c1-6-19(4)11-13(22)16-15(17(19)23)12(21)10-14-18(2,3)8-7-9-20(14,16)5/h6,12-14,17,21-23H,1,7-11H2,2-5H3/t12-,13+,14+,17-,19+,20+/m1/s1
|
|
InChIKey |
PEVPTRLNHNJRMF-FKSZAOESSA-N
|
|
Synonyms |
Sphaeropsidin E; CHEBI:69497; Q27137837; (1S,2R,4S,4bS,8aS,10R)-2-ethenyl-2,4b,8,8-tetramethyl-3,4,5,6,7,8a,9,10-octahydro-1H-phenanthrene-1,4,10-triol
|
|
CAS | NA | |
PubChem CID | 10947171 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 320.5 | ALogp: | 2.8 |
HBD: | 3 | HBA: | 3 |
Rotatable Bonds: | 1 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 60.7 | Aromatic Rings: | 3 |
Heavy Atoms: | 23 | QED Weighted: | 0.641 |
Caco-2 Permeability: | -4.836 | MDCK Permeability: | 0.00001810 |
Pgp-inhibitor: | 0.932 | Pgp-substrate: | 0.996 |
Human Intestinal Absorption (HIA): | 0.008 | 20% Bioavailability (F20%): | 0.381 |
30% Bioavailability (F30%): | 0.016 |
Blood-Brain-Barrier Penetration (BBB): | 0.501 | Plasma Protein Binding (PPB): | 76.04% |
Volume Distribution (VD): | 1.826 | Fu: | 26.70% |
CYP1A2-inhibitor: | 0.021 | CYP1A2-substrate: | 0.154 |
CYP2C19-inhibitor: | 0.02 | CYP2C19-substrate: | 0.832 |
CYP2C9-inhibitor: | 0.061 | CYP2C9-substrate: | 0.177 |
CYP2D6-inhibitor: | 0.008 | CYP2D6-substrate: | 0.117 |
CYP3A4-inhibitor: | 0.535 | CYP3A4-substrate: | 0.281 |
Clearance (CL): | 6.097 | Half-life (T1/2): | 0.068 |
hERG Blockers: | 0.284 | Human Hepatotoxicity (H-HT): | 0.082 |
Drug-inuced Liver Injury (DILI): | 0.075 | AMES Toxicity: | 0.034 |
Rat Oral Acute Toxicity: | 0.98 | Maximum Recommended Daily Dose: | 0.998 |
Skin Sensitization: | 0.399 | Carcinogencity: | 0.809 |
Eye Corrosion: | 0.512 | Eye Irritation: | 0.636 |
Respiratory Toxicity: | 0.985 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC002921 | 0.472 | D04VIS | 0.265 | ||||
ENC002832 | 0.376 | D0Y2YP | 0.250 | ||||
ENC001070 | 0.365 | D0L2LS | 0.248 | ||||
ENC002831 | 0.363 | D0KR5B | 0.245 | ||||
ENC002083 | 0.363 | D0Q6NZ | 0.245 | ||||
ENC002266 | 0.356 | D05BTM | 0.243 | ||||
ENC000946 | 0.352 | D08SVH | 0.243 | ||||
ENC002221 | 0.351 | D0T2PL | 0.243 | ||||
ENC002923 | 0.350 | D04SFH | 0.240 | ||||
ENC005921 | 0.348 | D0I2SD | 0.240 |